(The scientific sessions were held Nov. 12-16 in Orlando.)

Company (Location)

Product

Description

Indication

Status (Date)#


Amarin Corp. plc (Dublin, Ireland)

AMR101

A prescription-grade omega-3 fatty acid

High triglycerides

Phase III data showed patients who were on statin therapy experienced a significant reduction in triglyceride levels and other lipid parameters, as well as inflammatory biomarkers, when treated with AMR101 (11/17)

Genzyme Corp. (Cambridge, Mass.)

MIPO

Mipomersen

Low-density lipoprotein cholesterol

Positive results from a randomized, double-blind, placebo-controlled Phase II trial showed that weekly treatment reduced LDL-C by 47% compared to 2% with placebo (11/17)

Regado Biosciences Inc. (Basking Ridge, N.J.)

REG1

Anticoagulant system; reversible antithrombotic agent

Cardiovascular disease

Phase IIb data suggested it provided nearly complete Factor IXa inhibition with a dose of 1 mg/kg of pegnivacogin and, when followed by 75% and 100% reversal doses of anivamersen, resulted in numerically lower rates of ischemic events compared with heparin (11/16)


Notes:

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue.

# The date indicated refers to the BioWorld Today issue in which the news item can be found.